Ewing’s sarcoma family of tumors in Finland during 1990–2009: A population-based study

Abstract

Population-based studies including both bone and soft tissue ESFTs are few. In this nationwide, population-based study on Finnish bone and soft tissue ESFT patients, we find their treatment successful and results comparable to those previously published. Absence of metastases, young age at diagnosis and a peripheral primary tumor site were associated with a better prognosis. It seems that surgical resection of the primary tumor should be performed whenever adequate resection margins can be achieved. The role of high dose chemotherapy merits further studies in this setting.

Referral patterns, treatment and outcome of high‐grade malignant bone sarcoma in Scandinavia—SSG Central Register 25 years' experience

“…For Ewing sarcoma, the overall survival in both localized and metastatic disease has improved since 1990s, as indicated in other publications . More intensive chemotherapy (including high‐dose chemotherapy with stem cell support), advanced surgery and radiotherapy as well as surgery on lung metastases have all contributed to improved outcomes .…”

Clinical Analysis of Primary Primitive Neuroectodermal Tumors in the Female Genital Tract

“…16 However, the latest population-based study showed that adding preoperative or postoperative radiation therapy to a surgical resection with at least a marginal margin did not improve outcome. 17 In our cases, 10 patients underwent local surgical resection including total hysterectomy with bilateral salpingo-oophorectomy with or without pelvic lymphadenectomy. Multiple chemotherapy regimens for treatment of PNETs have been reported, most of them based on trials of bone PNETs.…”

Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT

“…Current response rates of Ewing's sarcoma family of tumour (ESFT) patients to first-line chemotherapy are as high as 77% (Bacci et al , 2000; Yonemori et al , 2007; Gaspar et al , 2012; Serlo et al , 2012), demonstrating that some ESFTs are chemoresponsive. However, others are resistant to chemotherapy at diagnosis (23%), and this is known as intrinsic resistance.…”